BMO Capital Markets reiterated their outperform rating on shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) in a research note issued to investors on Wednesday, July 12th. They currently have a $62.00 price target on the stock, up from their previous price target of $59.00.
Several other research analysts also recently weighed in on the company. TheStreet upgraded Ionis Pharmaceuticals from a d+ rating to a c- rating in a research note on Wednesday, July 5th. Vetr downgraded Ionis Pharmaceuticals from a hold rating to a sell rating and set a $37.67 price target for the company. in a research note on Monday, April 3rd. Needham & Company LLC reiterated a buy rating and set a $64.00 price target on shares of Ionis Pharmaceuticals in a research note on Wednesday, May 17th. Leerink Swann restated an outperform rating and issued a $45.00 target price (down previously from $47.00) on shares of Ionis Pharmaceuticals in a research note on Wednesday, May 17th. Finally, Zacks Investment Research upgraded Ionis Pharmaceuticals from a hold rating to a buy rating and set a $58.00 target price for the company in a research note on Wednesday, July 12th. Three investment analysts have rated the stock with a sell rating, six have issued a hold rating and six have given a buy rating to the stock. The stock presently has an average rating of Hold and a consensus price target of $47.13.
Shares of Ionis Pharmaceuticals (NASDAQ IONS) traded up 2.63% during midday trading on Wednesday, hitting $46.76. 2,627,979 shares of the stock were exchanged. Ionis Pharmaceuticals has a 1-year low of $24.58 and a 1-year high of $60.01. The stock’s 50-day moving average price is $52.52 and its 200-day moving average price is $46.92. The firm has a market capitalization of $5.80 billion, a price-to-earnings ratio of 224.81 and a beta of 3.14.
Ionis Pharmaceuticals (NASDAQ:IONS) last posted its quarterly earnings results on Tuesday, August 8th. The company reported ($0.09) earnings per share for the quarter, missing the consensus estimate of ($0.06) by $0.03. The firm had revenue of $104.15 million for the quarter, compared to the consensus estimate of $93.29 million. Ionis Pharmaceuticals had a return on equity of 17.34% and a net margin of 5.25%. The firm’s revenue was up 170.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.47) EPS. On average, analysts forecast that Ionis Pharmaceuticals will post ($0.02) EPS for the current year.
In other news, SVP C Frank Bennett sold 10,000 shares of Ionis Pharmaceuticals stock in a transaction dated Monday, July 24th. The stock was sold at an average price of $59.29, for a total transaction of $592,900.00. Following the completion of the sale, the senior vice president now owns 25,041 shares in the company, valued at approximately $1,484,680.89. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Chairman Stanley T. Crooke sold 16,500 shares of the firm’s stock in a transaction dated Monday, July 17th. The shares were sold at an average price of $52.45, for a total value of $865,425.00. Following the transaction, the chairman now directly owns 53,014 shares in the company, valued at $2,780,584.30. The disclosure for this sale can be found here. In the last quarter, insiders have sold 54,379 shares of company stock valued at $2,946,052. Corporate insiders own 1.86% of the company’s stock.
Several large investors have recently added to or reduced their stakes in IONS. Russell Investments Group Ltd. purchased a new stake in Ionis Pharmaceuticals during the fourth quarter valued at $976,000. Comerica Bank raised its stake in Ionis Pharmaceuticals by 33.3% in the fourth quarter. Comerica Bank now owns 16,505 shares of the company’s stock valued at $794,000 after buying an additional 4,122 shares in the last quarter. Dimensional Fund Advisors LP raised its stake in Ionis Pharmaceuticals by 361.7% in the fourth quarter. Dimensional Fund Advisors LP now owns 97,341 shares of the company’s stock valued at $4,656,000 after buying an additional 76,259 shares in the last quarter. GSA Capital Partners LLP purchased a new stake in Ionis Pharmaceuticals during the fourth quarter valued at $533,000. Finally, Norges Bank purchased a new stake in Ionis Pharmaceuticals during the fourth quarter valued at $50,976,000. Institutional investors own 88.77% of the company’s stock.
About Ionis Pharmaceuticals
Ionis Pharmaceuticals, Inc is engaged in discovering and developing ribonucleic acid (RNA)-targeted therapeutics. The Company, using its drug discovery platform, has developed a pipeline of drugs for patients with unmet medical needs. The Company’s segments include Ionis Core and Akcea Therapeutics. In the Ionis Core segment, the Company is engaged in exploiting a drug discovery platform to generate a pipeline of drugs for the Company and its partners.
What are top analysts saying about Ionis Pharmaceuticals Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Ionis Pharmaceuticals Inc. and related companies.